ARS Pharmaceuticals
SPRY
SPRY
97 hedge funds and large institutions have $252M invested in ARS Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
11.51% more ownership
Funds ownership: 58.11% → 69.62% (+12%)
5% more funds holding
Funds holding: 92 → 97 (+5)
32% less capital invested
Capital invested by funds: $369M → $252M (-$117M)
Holders
97
Holding in Top 10
3
Calls
$4.33M
Puts
$3.83M
Top Buyers
| 1 | +$24.4M | |
| 2 | +$16.1M | |
| 3 | +$14.6M | |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$4.84M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.47M |
Top Sellers
| 1 | -$12.7M | |
| 2 | -$8.16M | |
| 3 | -$2.04M | |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$1.84M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.63M |